ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2026
Integrated multi-omics profiling reveals the potential role of maternal systemic immune dysregulation driven by monocyte/macrophage in preeclampsia.
Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPreeclampsia (PE) is a leading cause of maternal morbidity and mortality, but the coordinated dysregulation between the placental unit and the maternal systemic immune response remains incompletely understood. An integrated multi-omics approach is required to decipher these cross-tissue interactions.
methodsWe performed an integrated analysis of bulk transcriptome data from 810 pregnancies (299 placental tissues and 511 blood samples). Additionally, to gain mechanistic insights at cellular resolution, we analyzed single-cell RNA sequencing (scRNA-seq) data from maternal endometrial biopsies (from non-pregnant women with a history of PE or Normal, n = 21) and peripheral blood mononuclear cells (PBMCs, n = 10). Analytical methods included differential expression analysis, pathway enrichment, machine learning-based predictive modeling, and cell–cell communication inference.
resultsAnalysis of bulk transcriptomes from placental and blood specimens identified 25 core genes consistently associated with PE. A Random Forest model constructed with these genes demonstrated high predictive accuracy (AUC > 0.96 in both tissue and blood) and was validated in an independent cohort (AUC = 0.775). To explore the cellular basis of this signature, we turned to scRNA-seq data. Analysis of maternal endometrium and PBMCs identified a reconfigured immune microenvironment, characterized by an increased proportion of LYZ + monocytes in endometrium from women with a history of PE. A key finding was the significant downregulation of the coagulation factor F13A1 within monocyte/macrophage lineages across both bulk and single-cell datasets. Cell–cell communication analysis further suggested that monocytes/macrophages may regulate immune and endothelial cells through dysregulated COMPLEMENT and GALECTIN signaling pathways.
conclusionOur study defines a robust, placenta-blood based gene signature for PE. Exploratory analysis of maternal endometrial and immune cells at single-cell resolution provides preliminary evidence that monocyte/macrophage dysfunction, including F13A1 downregulation, may be a pervasive feature of PE pathophysiology, observable even in maternal tissues beyond the placenta. These findings highlight the potential of cross-tissue biomarkers and justify further investigation into the systemic role of myeloid cells in PE.
Indexed as
Identifiers
42050225What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.